Please use this identifier to cite or link to this item:
http://hdl.handle.net/2445/122636
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Tarrado Castellarnau, Míriam Neus | - |
dc.contributor.author | Atauri Carulla, Ramón de | - |
dc.contributor.author | Tarragó-Celada, Josep | - |
dc.contributor.author | Perarnau, Jordi | - |
dc.contributor.author | Yuneva, Mariia | - |
dc.contributor.author | Thomson, Timothy M. | - |
dc.contributor.author | Cascante i Serratosa, Marta | - |
dc.date.accessioned | 2018-05-29T11:57:52Z | - |
dc.date.available | 2018-05-29T11:57:52Z | - |
dc.date.issued | 2017-10-04 | - |
dc.identifier.issn | 1744-4292 | - |
dc.identifier.uri | http://hdl.handle.net/2445/122636 | - |
dc.description.abstract | Cyclin‐dependent kinases (CDK) are rational cancer therapeutic targets fraught with the development of acquired resistance by tumor cells. Through metabolic and transcriptomic analyses, we show that the inhibition of CDK4/6 leads to a metabolic reprogramming associated with gene networks orchestrated by the MYC transcription factor. Upon inhibition of CDK4/6, an accumulation of MYC protein ensues which explains an increased glutamine metabolism, activation of the mTOR pathway and blunting of HIF‐1α‐mediated responses to hypoxia. These MYC‐driven adaptations to CDK4/6 inhibition render cancer cells highly sensitive to inhibitors of MYC, glutaminase or mTOR and to hypoxia, demonstrating that metabolic adaptations to antiproliferative drugs unveil new vulnerabilities that can be exploited to overcome acquired drug tolerance and resistance by cancer cells. | - |
dc.format.extent | 15 p. | - |
dc.format.mimetype | application/pdf | - |
dc.language.iso | eng | - |
dc.publisher | EMBO Press | - |
dc.relation.isformatof | Reproducció del document publicat a: https://doi.org/10.15252/msb.20167321 | - |
dc.relation.ispartof | Molecular Systems Biology, 2017, vol. 13, num. 10, p. 940 | - |
dc.relation.uri | https://doi.org/10.15252/msb.20167321 | - |
dc.rights | cc-by (c) Tarrado Castellarnau, Míriam Neus et al., 2017 | - |
dc.rights.uri | http://creativecommons.org/licenses/by/3.0/es | - |
dc.source | Articles publicats en revistes (Bioquímica i Biomedicina Molecular) | - |
dc.subject.classification | Càncer | - |
dc.subject.classification | Transducció de senyal cel·lular | - |
dc.subject.other | Cancer | - |
dc.subject.other | Cellular signal transduction | - |
dc.title | De novo MYC addiction as an adaptive response of cancer cells to CDK4/6 inhibition | - |
dc.type | info:eu-repo/semantics/article | - |
dc.type | info:eu-repo/semantics/publishedVersion | - |
dc.identifier.idgrec | 673713 | - |
dc.date.updated | 2018-05-29T11:57:52Z | - |
dc.rights.accessRights | info:eu-repo/semantics/openAccess | - |
dc.identifier.pmid | 28978620 | - |
Appears in Collections: | Articles publicats en revistes (Bioquímica i Biomedicina Molecular) |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
673713.pdf | 3.26 MB | Adobe PDF | View/Open |
This item is licensed under a Creative Commons License